Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare... see more

NDAQ:INM - Post Discussion

InMed Pharmaceuticals Inc > Adams' Options
View:
Post by Stevemin on Apr 16, 2021 3:57pm

Adams' Options

Adams has about 60k options (at an exercise price of $2.02 US) that are expiring next month (5/15). Will be very interesting to see if he exercises any of them. At that cheap of a price, if he chooses NOT to exercise any of them, then I'd say there is a sh&t ton of trouble on the ol' Inmed homefront.

Either way, he's got to go. Now.
Comment by gainwidpatience on Apr 17, 2021 5:02pm
Adam will repeat his same old story on April 28, which is going to be same even next year - future will be bright for Inmed.. we are having some exciting things coming up.. we are pursuing licensing opportunities with intregrasyn... blah blah. the moment he took the last pp at lower price which was unnecessary, it was evident that this year is going to be flat as usual.